Haemonetics announced today that it completed its previously announced acquisition of Attune Medical. Boston-based Haemonetics agreed to buy Attune for an upfront cash payment of $160 million just under a month ago. Chicago-based Attune medical develops the ensoETM proactive esophageal cooling device. The company designed ensoETM to reduce the likelihood of ablation-related esophageal injury. These […]
Attune Medical
Haemonetics agrees to acquire esophagus-protecting device maker Attune Medical
Haemonetics announced today that it entered into an agreement to acquire Attune Medical. Boston-based Haemonetics agreed to buy Attune for an upfront cash payment of $160 million. The deal also includes additional contingent consideration based on sales growth in the three years following the consummation of the acquisition. These additional payments also hinge on other […]
Study backs esophagus-protecting device from Attune Medical
Attune Medical today announced positive data supporting the use of its ensoETM proactive esophageal cooling device. Chicago-based Attune designed ensoETM to reduce the likelihood of ablation-related esophageal injury. These injuries occur as a result of radiofrequency (RF) cardiac ablation procedures. ensoETM received FDA investigational device exemption (IDE) for this indication just over one year ago. The […]
FDA authorizes Attune Medical’s ensoETM for use in RF ablation procedures
Attune Medical announced today that it received FDA de novo marketing authorization for its ensoETM device in ablation procedures. Chicago-based Attune designed ensoETM to reduce the likelihood of ablation-related esophageal injury. These injuries occur as a result of radiofrequency (RF) cardiac ablation procedures. ensoETM received FDA investigational device exemption (IDE) for this indication just over […]
Attune Medical wins FDA IDE nod to evaluate ensoETM in radiofrequency ablation procedures
Attune Medical announced today that the FDA granted investigational device exemption (IDE) to study the company’s ensoETM. Chicago-based Attune designed ensoETM to reduce esophageal thermal injury during cardiac radiofrequency (RF) ablation procedures. The IMPACT II study is underway in Europe and already enrolled nearly 20 patients. Attune said in a news release that the single-use […]
Attune Medical closes $16m Series C
Attune Medical said today it closed a $15.5 million oversubscribed Series C round of financing,. Funds from the round are slated to support expansion and progression of the company’s temperature management technology, including its flagship EnsoETM esophageal cooling device. The EnsoETM is designed to control patient temperature through a system inserted into the esophagus, which […]
5 medtech stories we missed this week: Jan. 26, 2018
From Attune Medical receiving FDA 510(k) clearance to Synapse Medical having CE Mark approval, here are 5 medtech stories we missed this week but thought were still worth mentioning. 1. Attune Medical gets FDA 510(k) clearance Attune Medical announced in a Jan. 8 press release that it has received FDA 510(k) clearance for its EnsoETM […]
FDA expands indication for Attune Medical’s Enso esophageal temperature management device
Attune Medical said today that it won an expanded indication from the FDA for its Enso esophageal temperature management device. Formerly known as Advanced Cooling Therapy, Chicago-based Attune said the new indication covers extended duration of use for up to 72 hours. The triple lumen system is designed to be inserted into the esophagus, with two lumens […]
